The evidence shows that 77–83%, 87–90% and 83–86% of psoriatic patients treated with secukinumab [12], ixekizumab [13] and brodalumab [14], respectively, reached a 75% reduction in the Psoriasis Area Severity Index (PASI) score; thereby, IL-17 inhibitors showed high efficacy. The gene discussed is IL17A; the disease is psoriasis.